Biological and behavioural determinants of the frequency of mild, biochemical hypoglycaemia in patients with Type 1 diabetes on multiple insulin injection therapy

Author(s):  
Maureen M. J. Janssen ◽  
Frank J. Snoek ◽  
Renate T. de Jongh ◽  
Sandrina Casteleijn ◽  
Walter Devill� ◽  
...  
2020 ◽  
Vol 11 (1) ◽  
pp. 17
Author(s):  
Yousef Al Zoubi ◽  
Bashair M. Mussa ◽  
Ankita Srivastava ◽  
Abdul Khader Mohammed ◽  
Elamin Abdelgadir ◽  
...  

The recurrence of hypoglycemic episodes leads to attenuation of the normal counter-regulatory mechanisms that are controlled by the hypothalamus, which results in hypoglycemia unawareness (HU). In this case report, we described for the first time the differential expression of TNF-α, IL-1β, IL-6, and IFN-γ in a blood sample that was taken from a 27-year-old patient with type 1 diabetes mellitus (T1DM) who was diagnosed with HU. The anti-diabetic regimen is currently based on insulin injection, but the patient is planning to start the use of an insulin pump to have better control of glucose levels. Our results showed a trend toward an increase in the expression of IL-1β, IL-6, and IFN-γ in T1DM patient with HU. However, the mRNA level of TNF-α showed a significant decrease. These observations suggest that systemic inflammation could be an underlying cause of HU.


Cells ◽  
2021 ◽  
Vol 10 (7) ◽  
pp. 1589
Author(s):  
Ryota Inoue ◽  
Kuniyuki Nishiyama ◽  
Jinghe Li ◽  
Daisuke Miyashita ◽  
Masato Ono ◽  
...  

Stem cell therapy using islet-like insulin-producing cells derived from human pluripotent stem cells has the potential to allow patients with type 1 diabetes to withdraw from insulin therapy. However, several issues exist regarding the use of stem cell therapy to treat type 1 diabetes. In this review, we will focus on the following topics: (1) autoimmune responses during the autologous transplantation of stem cell-derived islet cells, (2) a comparison of stem cell therapy with insulin injection therapy, (3) the impact of the islet microenvironment on stem cell-derived islet cells, and (4) the cost-effectiveness of stem cell-derived islet cell transplantation. Based on these various viewpoints, we will discuss what is required to perform stem cell therapy for patients with type 1 diabetes.


2018 ◽  
Vol 19 (8) ◽  
pp. 1459-1466 ◽  
Author(s):  
Marie‐Anne Burckhardt ◽  
Grant J. Smith ◽  
Matthew N. Cooper ◽  
Timothy W. Jones ◽  
Elizabeth A. Davis

Sign in / Sign up

Export Citation Format

Share Document